1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 40 at diagnostic biopsy
Sponsor: NCI
Protocol IDs: COG-AOST0331, AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20
|
|
2.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to 18
Sponsor: NCI
Protocol IDs: COG-ACCL0431, ACCL0431, NCT00716976
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: OS2008, NCT00667342
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-302, NCT00538239
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 50
Sponsor: Pharmaceutical / Industry
Protocol IDs: TR02-2421, NCT00102531
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0230, 07-C-0230, NCT00550654
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 74
Sponsor: Other
Protocol IDs: SARC012, D8180C00039, NCT00752206
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-1299, NCT00802880
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCCWFU-71108, CCCWFU 71108, IRB00008212, NCT00974545
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0121, NCI-41, 41, NCT00020163
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
19.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-07-C-0040, NCI-P6981, NCT00428272
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 16
Sponsor: NCI
Protocol IDs: NCI-07-C-0054, NCT00437047
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-08-C-0007, 08-C-0007, NCI-P6068, 7458, NCT00556881
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-091, NCT00927966
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000449681, CASE-CCF-7509, CASE-CCF-1062, NCT00311558
|
|
25.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: JHOC-J0685, NA_00003073, J0685, NCT00499733
|
